Locoregional extension and patterns of failure for nasopharyngeal carcinoma with intracranial extension

•NPC with intracranial extension spreads follow an orderly pattern.•Patterns of failure for NPC with intracranial extension after IMRT were analyzed.•Clinical target volume reduction may be feasible for selected patients. To evaluate the locoregional extension and patterns of failure for nasopharyng...

Full description

Saved in:
Bibliographic Details
Published in:Oral oncology 2018-04, Vol.79, p.27-32
Main Authors: Cao, Caineng, Jiang, Feng, Jin, Qifeng, Jin, Ting, Huang, Shuang, Hu, Qiaoying, Chen, Yuanyuan, Piao, Yongfeng, Hua, Yonghong, Feng, Xinglai, Chen, Xiaozhong
Format: Article
Language:English
Subjects:
Adolescent
Adult
Aged
Clinical target volume
Female
Humans
Local extension
Lymph node spread
Lymphatic Metastasis
Magnetic Resonance Imaging
Male
Middle Aged
Nasopharyngeal carcinoma
Nasopharyngeal Carcinoma - pathology
Nasopharyngeal Carcinoma - radiotherapy
Nasopharyngeal Neoplasms - diagnostic imaging
Nasopharyngeal Neoplasms - pathology
Nasopharyngeal Neoplasms - radiotherapy
Prognosis
Radiotherapy, Intensity-Modulated
Skull - pathology
Survival Analysis
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•NPC with intracranial extension spreads follow an orderly pattern.•Patterns of failure for NPC with intracranial extension after IMRT were analyzed.•Clinical target volume reduction may be feasible for selected patients. To evaluate the locoregional extension and patterns of failure for nasopharyngeal carcinoma (NPC) with intracranial extension to improve clinical target volume (CTV) delineation. A total of 205 NPC patients with intracranial extension by magnetic resonance imaging (MRI) were retrospectively reviewed. According to the cumulative incidence rates of tumor invasion, we initially classified anatomic sites surrounding the nasopharynx into three risk grades: high risk (≥35%), medium risk (≥10–35%), and low risk (
ISSN:1368-8375
1879-0593
DOI:10.1016/j.oraloncology.2018.02.004